38585774|t|Network medicine informed multi-omics integration identifies drug targets and repurposable medicines for Amyotrophic Lateral Sclerosis.
38585774|a|Amyotrophic Lateral Sclerosis (ALS) is a devastating, immensely complex neurodegenerative disease by lack of effective treatments. To date, the challenge to establishing effective treatment for ALS remains formidable, partly due to inadequate translation of existing human genetic findings into actionable ALS-specific pathobiology for subsequent therapeutic development. This study evaluates the feasibility of network medicine methodology via integrating human brain-specific multi-omics data to prioritize drug targets and repurposable treatments for ALS. Using human brain-specific genome-wide quantitative trait loci (x-QTLs) under a network-based deep learning framework, we identified 105 putative ALS-associated genes enriched in various known ALS pathobiological pathways, including regulation of T cell activation, monocyte differentiation, and lymphocyte proliferation. Specifically, we leveraged non-coding ALS loci effects from genome-wide associated studies (GWAS) on brain-specific expression quantitative trait loci (QTL) (eQTL), protein QTLs (pQTL), splicing QTL (sQTL), methylation QTL (meQTL), and histone acetylation QTL (haQTL). Applying network proximity analysis of predicted ALS-associated gene-coding targets and existing drug-target networks under the human protein-protein interactome (PPI) model, we identified a set of potential repurposable drugs (including Diazoxide, Gefitinib, Paliperidone, and Dimethyltryptamine) for ALS. Subsequent validation established preclinical and clinical evidence for top-prioritized repurposable drugs. In summary, we presented a network-based multi-omics framework to identify potential drug targets and repurposable treatments for ALS and other neurodegenerative disease if broadly applied.
38585774	105	134	Amyotrophic Lateral Sclerosis	Disease	MESH:D000690
38585774	136	165	Amyotrophic Lateral Sclerosis	Disease	MESH:D000690
38585774	167	170	ALS	Disease	MESH:D000690
38585774	208	233	neurodegenerative disease	Disease	MESH:D019636
38585774	330	333	ALS	Disease	MESH:D000690
38585774	403	408	human	Species	9606
38585774	442	445	ALS	Disease	MESH:D000690
38585774	593	598	human	Species	9606
38585774	690	693	ALS	Disease	MESH:D000690
38585774	701	706	human	Species	9606
38585774	841	844	ALS	Disease	MESH:D000690
38585774	888	891	ALS	Disease	MESH:D000690
38585774	1055	1058	ALS	Disease	MESH:D000690
38585774	1335	1338	ALS	Disease	MESH:D000690
38585774	1414	1419	human	Species	9606
38585774	1524	1533	Diazoxide	Chemical	MESH:D003981
38585774	1535	1544	Gefitinib	Chemical	MESH:D000077156
38585774	1546	1558	Paliperidone	Chemical	MESH:D000068882
38585774	1564	1582	Dimethyltryptamine	Chemical	MESH:D004130
38585774	1588	1591	ALS	Disease	MESH:D000690
38585774	1831	1834	ALS	Disease	MESH:D000690
38585774	1845	1870	neurodegenerative disease	Disease	MESH:D019636
38585774	Negative_Correlation	MESH:D000068882	MESH:D000690
38585774	Negative_Correlation	MESH:D000077156	MESH:D000690
38585774	Negative_Correlation	MESH:D003981	MESH:D000690
38585774	Negative_Correlation	MESH:D004130	MESH:D000690

